Business
AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress
AI-Derived AlloView Results Correlate with Presence and Type of Biopsy Proven Kidney Rejection Longitudinal Monitoring with AlloSure Kidney Enables Earlier
About this update from Caredx, Inc.
[{"type":"text","content":"\nAI-Derived AlloView Results Correlate with Presence and Type of Biopsy Proven Kidney Rejection \n\n\nLongitudinal Monitoring with AlloSure Kidney Enables Earlier Identification of Graft Injury and Assessment of Rejection Treatment \n\n\nKOAR Data Show Kidney Biopsies Informed by AlloSure Detect More Acute Rejection than Biopsies Based on Traditional Indications \n\n\n BRISBANE, Calif.--(BUSINESS WIRE)--\nCareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new data to be presented at the 2024 American Transplant Congress (ATC) being held June 1-5 in Philadelphia.\n\n\nCareDx solutions are featured in 36 oral presentations and posters, and a symposium. The findings highlight innovative approaches, including AI integration, and the real-world clinical utility of CareDx’s solutions, emphasizing their significant impact on patient care and outcomes in kidney, heart, and lung transplantation.\n\n\n“The additive value of artificial intelligence to our transplant solutions holds significant promise,” said John W. Hanna, CareDx President and CEO. “We are proud to have a leading presence at ATC and showcase new data on AI-enabled rejection monitoring, the clinical value of longitudinal monitoring with AlloSure Kidney, and the potential for biopsy reductions with AlloSure Kidney in real-world settings.”\n\n\nKey data to be presented at 2024 ATC:\n\n\n\nUtilization of Artificial Intelligence (AI) in Predicting the Risk of Kidney Allograft Rejection, S. V. Shah, S. Voora, P. J. Hanson, et al. Poster Abstract Session D148. This independent study establishes reference values for AlloView™, correlating results with the presence and type of allograft rejection observed on kidney biopsies. AlloView is the first AI-derived model to predict rejection risk in kidney transplant patients by integrating AlloSure Kidney with other clinical and laboratory factors associated with rejection.\n\n\n\nTime-Varying Relative Changes in Donor-Derived Cell-Free DNA (dd-cfDNA) during Rejection and dnDSA Detection in Primary and Repeat Kidney Transplant Recipients (KTR), S. Parajuli, N. Garg, K. Pinney, et al. Poster Abstract Session A184. This s...